ERRATUM

Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence

THOMAS SJ CRABTREE, RALPH A DEFRONZO, ROBERT EJ RYDER, CLIFFORD J BAILEY

Br J Diabetes 2020;**20**:28-31 https://doi.org/10.15277/bjd.2020.247

In the article listed above, there was an error in Figure 2. Please find below the corrected figure.

Figure 2. Forest plot showing meta-analysis of imeglimin versus placebo for (a) HbA_{1c} (%) and (b) fasting plasma glucose levels (mmol/L) using a random-effect model. Risk of bias assessment is also included

a) Study or subgroup	lme Mean	eglimi SD	n Total	Pl Mean	acebo SD	Total		. Mean difference V, random, 95% Cl	Year	Std. Mean difference IV, random, 95% CI
Pirags et al. 2012 (1) Fouqueray et al. 2013 Fouqueray et al. 2014	-0.18 -0.65 -0.6	0.9 0.82 0.99	31 68 81	0.31 -0.21 0.12	0.88 0.83 0.93	33 69 88	17.5% 37.6% 44.8%	-0.54 (-1.04, -0.04) -0.53 (-0.87, -0.19) -0.75 (-1.06, -0.43)	2012 2013 2014	
Total (95% CI)			180			190	100.0%	-0.63 (-0.84, -0.42)		•
Heterogeneity: $Tau^2 = 0.0$ Test for overall effect: $z =$				0.61); 12 :	= 0%					Favours Imeglimin Favours Placebo
) Study or subgroup	lme Mean	eglimi SD	n Total	Pl Mean	acebo SD	Total		. Mean difference V, random, 95% CI	Year	Std. Mean difference Risk of Bias IV, random, 95% CI A B C D E F 0
Pirags et al. 2012 (1) Fouqueray et al. 2013 Fouqueray et al. 2014	-1.02 -0.91 -0.93	2.38 1.96 2.79	31 67 81	0.78 0.36 -0.11	2.27 2.02 2.72	33 71 88	21.9% 36.6% 41.5%	-0.77 (-1.27, -0.26) -0.63 (-0.98, -0.29) -0.30 (-0.60, -0.01)	2012 2013 2014	
Total (95% CI)			179			192	100.0%	-0.52 (-0.80, -0.24)		
Heterogeneity: $Tau^2 = 0.0$ Test for overall effect: $z =$			= 2 (p =	0.19); 1 ² :	= 41%					-1 -0.5 0 0.5 1 Favours Imeglimin Favours Placebo
(1) SD absent therefo of variance given Figu					tudies	used ir	ı lieu (this is	s likely an overestima	ate	Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias